Synthesis and Biological Evaluation of 3-thiazolocoumarinyl Schiff-base Derivatives as Cholinesterase Inhibitors

Chemical Biology and Drug Design

Volumn 80, Issue 4, 2012, Pages 605-615

  Raza, Rabia ^a   Saeed, Aamer ^b   Arif, Mubeen ^b   Mahmood, Shamsul ^b   Muddassar, Muhammad ^c,d   Raza, Ahsan ^a   Iqbal, Jamshed ^a  

^a Tobe Camp University Road Abbottabad   (Pakistan)

^b QUAID I AZAM UNIVERSITY   (Pakistan)

^c Korea Institute for Advanced Study   (South Korea)

^d RIKEN   (Japan)

Author keywords

3 thiazolocoumarinyl Schiff Base; Acetylcholinesterase; Alzheimer's disease; Butyrylcholinesterase; Coumarin derivative

Indexed keywords

3 [2 (3 CHLORO 1 BENZYLIDENEHYDRAZINE)THIAZOL 4 YL] 2H CHROMEN 2 ONE; 3 [2 (4 BROMO 1 BENZYLIDENEHYDRAZINE)THIAZOL 4 YL] 2H CHROMEN 2 ONE; 3 [2 [2 (2 BENZYLOXYBENZYLIDENE)HYDRAZINYL]THIAZOL 4 YL] 2H CHROMEN 2 ONE; 3 [2 [2 (2 CHLOROBENZYLIDENE)HYDRAZINYL]THIAZOL 4 YL] 2H CHROMEN 2 ONE; 3 [2 [2 (3 BROMOBENZYLIDENE)HYDRAZINYL]THIAZOL 4 YL] 2H CHROMEN 2 ONE; 3 [2 [2 (3 METHOXYBENZYLIDENE)HYDRAZINYL]THIAZOL 4 YL] 2H CHROMEN 2 ONE; 3 [2 [2 (3,4,5 TRIMETHOXYBENZYLIDENE)HYDRAZINYL]THIAZOL 4 YL] 2H CHROMEN 2 ONE; 3 [2 [2 (4 CHLOROBENZYLIDENE)HYDRAZINYL]THIAZOL 4 YL] 2H CHROMEN 2 ONE; 3 [2 [2 (4 HYDROXY 3,5 DIMETHOXYBENZYLIDENE)HYDRAZINYL]THIAZOL 4 YL] 2H CHROMEN 2 ONE; 3 [2 [2 (4 METHOXYBENZYLIDENE)HYDRAZINYL]THIAZOL 4 YL] 2H CHROMEN 2 ONE; 3 [2 [2 (4 N,N DIMETHYLBENZYLIDENE)HYDRAZINYL]THIAZOL 4 YL] 2H CHROMEN 2 ONE; 3 [2 [2 (4 NITROBENZYLIDENE)HYDRAZINYL]THIAZOL 4 YL] 2H CHROMEN 2 ONE; ACETYLCHOLINESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; HYDROXYL GROUP; NOOTROPIC AGENT; SCHIFF BASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; ELECTROPHORUS; ENZYME ACTIVE SITE; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ACETYLCHOLINESTERASE; ANIMALS; BUTYRYLCHOLINESTERASE; CATALYTIC DOMAIN; CHOLINESTERASE INHIBITORS; COUMARINS; ELECTROPHORUS; HORSES; MOLECULAR DOCKING SIMULATION; SCHIFF BASES; THIAZOLES;

ELECTROPHORUS ELECTRICUS; EQUIDAE;

EID: 84866597643     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2012.01435.x     Document Type: Article

References (49)

1. Terry A.J., Buccafusco J.J. (2003) The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther;306:821-827.
2. Waldemar G., Dubois B., Emre M., Georges J., McKeith I.G., Rossor M., Scheltens P., Tariska P., Winblad B. (2007) Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol;14:1-26.
3. Tabert M.H., Liu X., Doty R.L., Serby M., Zamora D., Pelton G.H., Marder K., Albers M.W., Stern Y., Devanand D.P. (2005) A 10-item smell identification scale related to risk for Alzheimer's disease. Ann Neurol;58:155-160.
4. Castro A., Conde S., Rodriguez-Franco M.I., Martinez A. (2002) Non-cholinergic pharmacotherapy approaches to the future treatment of Alzheimer's disease. Mini RevMed Chem;2:37-50.
5. Johannsen P. (2004) Long-term cholinesterase inhibitor treatment of Alzheimer's disease. CNS Drugs;18:757-768.
6. Doraiswamy P.M. (2002) Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs;16:811-824.
7. Wilkinson D.G., Francis P.T., Schwam E., Payne-Parrish J. (2004) Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging;21:453-478.
8. Shvaloff A., Neuman E., Guez D. (1996) Lines of therapeutics research in Alzheimer's disease. Psychopharmacol Bull;32:343-352.
9. Wilcock G.K. (1996) Current approaches to the treatment of Alzheimer's disease. Neurodegeneration;5:505-509.
10. Perry E.K. (1986) The cholinergic hypothesis-ten years on. Br Med Bull;42:63-69.
11. Bartus R.T., Dean R.L., Beer B., Lippa A.S. (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science;217:408-414.
12. Winkler J., Thal L.J., Gage F.H., Fisher L.J. (1998) Cholinergic strategies for Alzheimer's disease. J Mol Med (Berl);76:555-567.
13. John V., Lieberburg I., Thorsett E.D. (1993) Alzheimer's disease: current therapeutic approaches. In: Bristol J.A., editor. Annual Reports in Medicinal Chemistry; 28. San Diego: Academic Press; p. 197-206.
14. Giacobini E. (2003) Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res;28:515-522.
15. Castro A., Martinez A. (2001) Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease. Mini Rev Med Chem;1:267-272.
16. Bolognesi M.L., Andrisano V., Bartolini M., Banzi R., Melchiorre C. (2005) Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-beta aggregation. J Med Chem;48:24-27.
17. Zhang N., Casida J.E. (2002) Novel irreversible butyrylcholinesterase inhibitors: 2-chloro-1-(substituted-phenyl)ethylphosphonic acids. Bioorg Med Chem;10:1281-1290.
18. Weinstock M. (1999) Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer's Disease. CNS Drugs;12:307-323.
19. Smyth T., Ramachandran V.N., Smyth W.F. (2009) A study of the antimicrobial activity of selected naturally occurring and synthetic coumarins. Int J Antimicrob Agents;33:421-426.
20. Belluti F., Fontana G., Dal B.L., Carenini N., Giommarelli C., Zunino F. (2010) Design, synthesis and anticancer activities of stilbene-coumarin hybrid compounds: identification of novel proapoptotic agents. Bioorg Med Chem;18:3543-3550.
21. Manvar A., Malde A., Verma J., Virsodia V., Mishra A., Upadhyay K., Acharya H., Coutinho E., Shah A. (2008) Synthesis, anti-tubercular activity and 3D-QSAR study of coumarin-4-acetic acid benzylidene hydrazides. Eur J Med Chem;43:2395-2403.
22. Zhou X., Wan X.B., Wan T., Kong L.Y. (2008) Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. Bioorg Med Chem;16:8011-8021.
23. Edenharder R., Speth C., Decker M., Kolodziej H., Kayser O., Platt K.L. (1995) Inhibition of mutagenesis of 2-amino-3-methylimidazo[4, 5-f]quinoline (IQ) by coumarins and furanocoumarins, chromanones and furanochromanones. Mutat Res;345:57-71.
24. Lee B.H., Clothier M.F., Dutton F.E., Conder G.A., Johnson S.S. (1998) Anthelmintic beta-hydroxyketoamides (BKAs). Bioorg Med Chem Lett;8:3317-3320.
25. Hoult J.R., Paya M. (1996) Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Gen Pharmacol;27:713-722.
26. Hwu J.R., Singha R., Hong S.C., Chang Y.H., Das A.R., Vliegen I., De Clercq E., Neyts J. (2008) Synthesis of new benzimidazole-coumarin conjugates as anti-hepatitis C virus agents. Antiviral Res;77:157-162.
27. Kalkhambkar R.G., Kulkarni G.M., Kamanavalli C.M., Premkumar N., Asdaq S.M., Sun C.M. (2008) Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins. Eur J Med Chem;43:2178-2188.
28. Radanyi C., Le Bras G., Messaoudi S., Bouclier C., Peyrat J.F., Brion J.D., Marsaud V., Renoir J.M., Alami M. (2008) Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (hsp90). Bioorg Med Chem Lett;18:2495-2498.
29. Wood W.J., Patterson A.W., Tsuruoka H., Jain R.K., Ellman J.A. (2005) Substrate activity screening: a fragment-based method for the rapid identification of nonpeptidic protease inhibitors. J Am Chem Soc;127:15521-15527.
30. Starcevic S., Kocbek P., Hribar G., Rizner T.L., Gobec S. (2011) Biochemical and biological evaluation of novel potent coumarin inhibitor of 17beta-HSD type 1. Chem Biol Interact;191:60-65.
31. Cheng J.F., Chen M., Wallace D., Tith S., Arrhenius T., Kashiwagi H., Ono Y., Ishikawa A., Sato H., Kozono T., Sato H., Nadzan A.M. (2004) Discovery and structure-activity relationship of coumarin derivatives as TNF-alpha inhibitors. Bioorg Med Chem Lett;14:2411-2415.
32. Chimenti F., Secci D., Bolasco A., Chimenti P., Granese A., Befani O., Turini P., Alcaro S., Ortuso F. (2004) Inhibition of monoamine oxidases by coumarin-3-acyl derivatives: biological activity and computational study. Bioorg Med Chem Lett;14:3697-3703.
33. Raj H.G., Parmar V.S., Jain S.C., Goel S., Poonam ????., Himanshu ????., Malhotra S., Singh A., Olsen C.E., Wengel J. (1998) Mechanism of biochemical action of substituted 4-methylbenzopyran-2-ones. Part I: dioxygenated 4-methyl coumarins as superb antioxidant and radical scavenging agents. Bioorg Med Chem;6:833-839.
34. Sarojini B.K., Krishna B.G., Darshanraj C.G., Bharath B.R., Manjunatha H. (2010) Synthesis, characterization, in vitro and molecular docking studies of new 2, 5-dichloro thienyl substituted thiazole derivatives for antimicrobial properties. Eur J Med Chem;45:3490-3496.
35. Andreani A., Rambaldi M., Leoni A., Locatelli A., Bossa R., Fraccari A., Galatulas I., Salvatore G. (1996) Potential antitumour agents. 24. Synthesis and pharmacological behavior of imidazo[2, 1-b]thiazole guanylhydrazones bearing at least one chlorine. J Med Chem;39:2852-2855.
36. Abdel-Aziz H.A., Abdel-Wahab B.F., El-Sharief Marwa A.M.Sh., Abdulla M.M. (2009) Synthesis and anti-arrhythmic activity of some piperidine-based 1, 3-thiazole, 1, 3, 4-thiadiazole, and 1, 3-thiazolo[2, 3-c]-1, 2, 4-triazole derivatives. Monatsh Chem;140:431-437.
37. Plouvier B., Houssin R., Hecquet B., Colson P., Houssier C., Waring M.J., Hénichart J.P., Bailly C. (1994) Antitumour combilexin. A thiazole-containing analog of netropsin linked to an acridine chromophore. Bioconjug Chem;5:475-481.
38. Kalkhambkar R.G., Kulkarni G.M., Shivkumar H., Rao R.N. (2007) Synthesis of novel triheterocyclic thiazoles as anti-inflammatory and analgesic agents. Eur J Med Chem;42:1272-1276.
39. Vijesh A.M., Isloor A.M., Prabhu V., Ahmad S., Malladi S. (2010) Synthesis, characterization and anti-microbial studies of some novel 2, 4-disubstituted thiazoles. Eur J Med Chem;45:5460-5464.
40. Rudolph J., Theis H., Hanke R., Endermann R., Johannsen L., Geschke F. (2001) seco-Cyclothialidines: new concise synthesis, inhibitory activity toward bacterial and human DNA topoisomerases, and antibacterial properties. J Med Chem;44:619-626.
41. Geronikaki A., Hadjipavlou-Litina D., Zablotskaya A., Segal I. (2007) Organosilicon-containing thiazole derivatives as potential lipoxygenase inhibitors and anti-inflammatory agents. Bioinorg Chem Appl;2007:92145:1-7.
42. Fink B.E., Mortensen D.S., Stauffer S.R., Aron Z.D., Katzenellenbogen J.A. (1999) Novel structural templates for oestrogen-receptor ligands and prospects for combinatorial synthesis of oestrogens. Chem Biol;6:205-219.
43. Kolb P., Irwin J.J. (2009) Docking screens: right for the right reasons? Curr Top Med Chem;9:755-770.
44. Ellman G.L., Courtney K.D., Andres V., Feather-Stone R.M. (1961) A new and rapid colourimetric determination of acetylcholinesterase activity. Biochem Pharmacol;7:88-95.
45. Wu S., Zhang Y. (2007) LOMETS: a local meta-threading-server for protein structure prediction. Nucleic Acids Res;35:3375-3382.
46. Wu S., Skolnick J., Zhang Y. (2007) Ab initio modelling of small proteins by iterative TASSER simulations. BMC Biol;5:1-10.
47. Zhang Y., Skolnick J. (2004) SPICKER: a clustering approach to identify near-native protein folds. J Comput Chem;25:865-871.
48. Moustakas D.T., Lang P.T., Pegg S., Pettersen E., Kuntz I.D., Brooijmans N., Rizzo R.C. (2006) Development and validation of a modular, extensible docking program: DOCK 5. J Comput Aided Mol Des;20:601-619.
49. Darvesh S., Hopkins D.A., Geula C. (2003) Neurobiology of butyrylcholinesterase. Nat Rev Neurosci;4:131-138.